Tchaikapharma High Quality Medicines, Inc.
BBSEBG:THQM8.80
EUR
+0.15
(+1.73%)
Tchaikapharma High Quality Medicines, Inc.
BSEBG:THQM
(Bulgarian Stock Exchange)
Recent
price
8.80
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
FRC
•
in mil. unless spec.Working Capital
FRC
•
in mil. unless spec.Growth Rates
FRC
•
in mil. unless spec.Quarterly Revenue
FRC
•
in mil. unless spec.Quarterly Earnings Per Share
FRC
•
in mil. unless spec.Quarterly Dividends Per Share
FRC
•
in mil. unless spec.- Similar Companies
- Business
- Tchaikapharma High Quality Medicines, Inc. is a Bulgaria-based pharmaceutical company engaged in the development, manufacture, registration, commercialization, and distribution of generic and branded prescription pharmaceuticals, over-the-counter medications, and health products. Founded in 1999 and headquartered in Sofia, Bulgaria, the company operates Good Manufacturing Practice (GMP)-certified production facilities in Sofia and Varna, supplying healthcare institutions, wholesalers, and retail pharmacies across Bulgaria, the European Union, the Western Balkans, Central and Eastern Europe, and select international markets. Tchaikapharma High Quality Medicines, Inc. structures its product portfolio across major therapeutic classes, comprising cardiovascular medications, such as angiotensin-converting enzyme (ACE) inhibitors, angiotensin receptor blockers, beta-blockers, antiarrhythmics, diuretics, and lipid-lowering statins; central nervous system agents, such as antidepressants, anxiolytics, antipsychotics, analgesics, and antiepileptic therapies; metabolic and endocrinology treatments, such as oral antidiabetics, DPP-4 inhibitors, and biguanide combinations; gastrointestinal therapies, such as proton pump inhibitors, antacids, and antispasmodics; antimicrobial and anti-infective formulations, such as broad-spectrum antibiotics and antifungals; respiratory medicines; and musculoskeletal, anti-inflammatory, and antirheumatic products. The company manufactures diverse finished dosage forms, including film-coated tablets, immediate- and modified-release tablets, hard gelatin capsules, sterile injectables, lyophilized preparations, and oral liquids; and provides contract development and manufacturing organization (CDMO) services, private-label manufacturing, analytical quality control, technology transfer, and regulatory dossier licensing to third-party pharmaceutical enterprises. In recent developments, Tchaikapharma High Quality Medicines, Inc. has accelerated the construction and qualification of a third major production facility in Plovdiv to scale up solid dosage and sterile injectable capacities for expanded European export operations; executed share capital increases via the capitalization of undistributed profits and statutory reserves to finance strategic capital expenditure programs; introduced new fixed-dose generic combination therapies in cardiology and metabolic disease management; and broadened its strategic licensing, distribution, and contract manufacturing partnerships with international pharmaceutical groups across European markets.